Efficacy and safety of sotalol in patients with refractory atrial fibrillation or flutter

D. M. Gallik, Soo G. Kim, Kevin J. Ferrick, J. A. Roth, John Devens Fisher

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Sotalol's usefulness in treatment of atrial fibrillation and atrial flutter is unproven. This study evaluated (1) the efficacy of sotalol in preventing recurrences of paroxysmal atrial fibrillation or atrial flutter and controlling ventricular rate (in chronic atrial fibrillation or relapse of paroxysmal atrial arrhythmias), (2) the safety of sotalol, ana (3) predictors of sotalol efficacy. Thirty-three patients, 28 with paroxysmal and five with chronic atrial fibrillation or atrial flutter, received an average dose of 265 ± 119 mg of oral sotalol per day. During a 10 ± 12 month follow-up, recurrence rate for paroxysmal arrhythmia was 64%, with a 50% recurrence at 4.6 months. For patients with chronic atrial fibrillation, ventricular rates were well controlled with sotalol administration (136 ± 33 beats/min versus 88 ± 23 beats/min; p = 0.04). No patient with chronic atrial fibrillation converted to sinus rhythm during the study. Side effects necessitated sotalol discontinuation in three patients. By multi-variate analysis, younger age, higher ejection fraction, and absence of hypertension independently predicted sotalol efficacy.

Original languageEnglish (US)
Pages (from-to)155-160
Number of pages6
JournalAmerican Heart Journal
Volume134
Issue number2 I
DOIs
StatePublished - 1997
Externally publishedYes

Fingerprint

Sotalol
Atrial Flutter
Atrial Fibrillation
Safety
Recurrence
Cardiac Arrhythmias
Hypertension

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Efficacy and safety of sotalol in patients with refractory atrial fibrillation or flutter. / Gallik, D. M.; Kim, Soo G.; Ferrick, Kevin J.; Roth, J. A.; Fisher, John Devens.

In: American Heart Journal, Vol. 134, No. 2 I, 1997, p. 155-160.

Research output: Contribution to journalArticle

Gallik, D. M. ; Kim, Soo G. ; Ferrick, Kevin J. ; Roth, J. A. ; Fisher, John Devens. / Efficacy and safety of sotalol in patients with refractory atrial fibrillation or flutter. In: American Heart Journal. 1997 ; Vol. 134, No. 2 I. pp. 155-160.
@article{20eb50bfc5e54e34bfd4ee4c2ed03fdd,
title = "Efficacy and safety of sotalol in patients with refractory atrial fibrillation or flutter",
abstract = "Sotalol's usefulness in treatment of atrial fibrillation and atrial flutter is unproven. This study evaluated (1) the efficacy of sotalol in preventing recurrences of paroxysmal atrial fibrillation or atrial flutter and controlling ventricular rate (in chronic atrial fibrillation or relapse of paroxysmal atrial arrhythmias), (2) the safety of sotalol, ana (3) predictors of sotalol efficacy. Thirty-three patients, 28 with paroxysmal and five with chronic atrial fibrillation or atrial flutter, received an average dose of 265 ± 119 mg of oral sotalol per day. During a 10 ± 12 month follow-up, recurrence rate for paroxysmal arrhythmia was 64{\%}, with a 50{\%} recurrence at 4.6 months. For patients with chronic atrial fibrillation, ventricular rates were well controlled with sotalol administration (136 ± 33 beats/min versus 88 ± 23 beats/min; p = 0.04). No patient with chronic atrial fibrillation converted to sinus rhythm during the study. Side effects necessitated sotalol discontinuation in three patients. By multi-variate analysis, younger age, higher ejection fraction, and absence of hypertension independently predicted sotalol efficacy.",
author = "Gallik, {D. M.} and Kim, {Soo G.} and Ferrick, {Kevin J.} and Roth, {J. A.} and Fisher, {John Devens}",
year = "1997",
doi = "10.1016/S0002-8703(97)70118-2",
language = "English (US)",
volume = "134",
pages = "155--160",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "2 I",

}

TY - JOUR

T1 - Efficacy and safety of sotalol in patients with refractory atrial fibrillation or flutter

AU - Gallik, D. M.

AU - Kim, Soo G.

AU - Ferrick, Kevin J.

AU - Roth, J. A.

AU - Fisher, John Devens

PY - 1997

Y1 - 1997

N2 - Sotalol's usefulness in treatment of atrial fibrillation and atrial flutter is unproven. This study evaluated (1) the efficacy of sotalol in preventing recurrences of paroxysmal atrial fibrillation or atrial flutter and controlling ventricular rate (in chronic atrial fibrillation or relapse of paroxysmal atrial arrhythmias), (2) the safety of sotalol, ana (3) predictors of sotalol efficacy. Thirty-three patients, 28 with paroxysmal and five with chronic atrial fibrillation or atrial flutter, received an average dose of 265 ± 119 mg of oral sotalol per day. During a 10 ± 12 month follow-up, recurrence rate for paroxysmal arrhythmia was 64%, with a 50% recurrence at 4.6 months. For patients with chronic atrial fibrillation, ventricular rates were well controlled with sotalol administration (136 ± 33 beats/min versus 88 ± 23 beats/min; p = 0.04). No patient with chronic atrial fibrillation converted to sinus rhythm during the study. Side effects necessitated sotalol discontinuation in three patients. By multi-variate analysis, younger age, higher ejection fraction, and absence of hypertension independently predicted sotalol efficacy.

AB - Sotalol's usefulness in treatment of atrial fibrillation and atrial flutter is unproven. This study evaluated (1) the efficacy of sotalol in preventing recurrences of paroxysmal atrial fibrillation or atrial flutter and controlling ventricular rate (in chronic atrial fibrillation or relapse of paroxysmal atrial arrhythmias), (2) the safety of sotalol, ana (3) predictors of sotalol efficacy. Thirty-three patients, 28 with paroxysmal and five with chronic atrial fibrillation or atrial flutter, received an average dose of 265 ± 119 mg of oral sotalol per day. During a 10 ± 12 month follow-up, recurrence rate for paroxysmal arrhythmia was 64%, with a 50% recurrence at 4.6 months. For patients with chronic atrial fibrillation, ventricular rates were well controlled with sotalol administration (136 ± 33 beats/min versus 88 ± 23 beats/min; p = 0.04). No patient with chronic atrial fibrillation converted to sinus rhythm during the study. Side effects necessitated sotalol discontinuation in three patients. By multi-variate analysis, younger age, higher ejection fraction, and absence of hypertension independently predicted sotalol efficacy.

UR - http://www.scopus.com/inward/record.url?scp=0030885578&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030885578&partnerID=8YFLogxK

U2 - 10.1016/S0002-8703(97)70118-2

DO - 10.1016/S0002-8703(97)70118-2

M3 - Article

C2 - 9313591

AN - SCOPUS:0030885578

VL - 134

SP - 155

EP - 160

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 2 I

ER -